Terra Innovatum Submits Advanced Nuclear Proposal to NYSERDA to Help New York State Meet 2040 Zero-Carbon Goal
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 29, 2025 / Terra Innovatum Srl ('Terra Innovatum,' or the 'Company'), a developer of micro-modular nuclear reactors, today announced the submission of its response to the New York State Energy Research and Development Authority's ('NYSERDA') Advanced Nuclear Request for Information ('RFI'). The submission outlines plans for selecting a potential test reactor site for the Company's first-of-a-kind micro-modular reactor, SOLO™, intent to establish a designated production unit, and further commercial deployment opportunities to support the state's zero-emissions electricity target by 2040. Unlike conventional reactors, the compact footprint, modular design, and ability to operate for 15 years without refueling make SOLO™ well-suited for integration into local energy systems.
In Picture: Rendering of 3 SOLOTM units covering an area of approximately 3,600sqft in a public plaza (totaling 3MWe - 12MWt with Co-Generation).
'We believe SOLO™ represents a pivotal advancement in clean energy infrastructure,' said Alessandro Petruzzi - Co-founder & CEO of Terra Innovatum. 'As electricity demand accelerates, driven by AI, data centers, and industrial manufacturing, solutions like SOLO™ will be critical to delivering reliable, zero-carbon power without placing additional strain on the grid. We are excited to showcase the promise of our technology in addressing the urgent energy needs for New York State and look forward to the opportunity to engage with NYSERDA on a potential test reactor site and deployment framework. Importantly, our response to NYSERDA marks the first of many steps toward deploying scalable, plug-and-play energy solutions across the U.S. and beyond. With its low-cost design, 24/7 output, and 15-year fuel cycle, SOLO™ is uniquely positioned to meet the needs of communities, government entities, and businesses seeking energy certainty in an increasingly electrified world.'
In Picture: Rendering of 500 SOLOTM units covering a total of 500 MWe - 2,000 MWt (Co-Generation) energy deployment.
Giordano Morichi - Partner, Chief Business Development Officer & Investor Relations at Terra Innovatum continued: 'We see SOLO™ as a transformative and strategic opportunity for New York State to become a national leader in deploying advanced nuclear technologies that enhance energy security, grid resilience, and climate justice. Designed for real-world application, SOLO™ leverages a proven supply chain built entirely on licensed components that have been widely used in the nuclear industry for over 60 years. This approach eliminates the timing and cost risks associated with unlicensed fuels or research-phase technologies with no commercial availability. SOLO™'s inherently safe architecture, scalable deployment model, and cost certainty uniquely positions it to power the State's industrial hubs, manufacturing sites, ports, transit systems, and data centers, while also revitalizing underserved urban and rural communities. It enables local energy independence, supports sustainable construction, and strengthens resilient infrastructure. In doing so, SOLO™ offers the Empire State a carbon-free, economically competitive energy backbone to meet New York clean energy goals at scale.'
'Safety is our top priority,' affirmed Cesare Frepoli - Co-Founder, COO & Director of Regulatory Affairs at Terra Innovatum. 'The compact footprint of SOLO™-approximately 30 ft x 30 ft-combined with its modularity and embedded safeguards, allows for seamless integration in a wide range of environments without the need for expansive emergency planning zones. Its innovative reactor core design is gas cooled by helium, incorporates licensed, off-the-shelf components and utilizes non-proliferant low-enriched uranium (LEU) fuel, which significantly reduces regulatory risk and enhances safety. There is also no water involved in the system, eliminating the risk of hydrogen generation or explosion. Additionally, on top of the various redundancies, the reactor's inherently low thermal output ensures it operates well below fuel melting thresholds, further reinforcing its passive safety profile,' Dr. Frepoli concluded.
SOLO™ can be deployed across a wide range of environments-including dense urban centers, critical infrastructure corridors, and remote industrial zones-without compromising public security. Its use of non-proliferant, licensed nuclear fuel and embedded safeguards ensures a secure and compliant solution. SOLO™ can be a powerful asset in supporting New York State's clean energy leadership while simultaneously reinforcing grid resilience, advancing environmental and energy priorities, and driving long-term, sustainable economic growth.
Guided by New York's Climate Leadership and Community Protection Act, which targets a zero-emissions electricity sector by 2040, NYSERDA's RFI seeks innovative nuclear solutions to support the state's energy transformation. Terra Innovatum's proposal outlines potential deployment scenarios for SOLO™, including site considerations, partners, timeline, and use cases. The Company remains open and eager to engage further with NYSERDA to help advance the role of advanced nuclear energy in New York's grid.
Recent Highlights
Terra Innovatum recently announced a proposed business combination with GSR III Acquisition Corp., positioning the Company to accelerate its mission of delivering zero-carbon, cost-efficient, and reliable power. SOLO™ is the first micro-modular reactor designed for operation on widely available Low-Enriched Uranium (LEU) and is built using commercial off-the-shelf components, enabling a simplified regulatory pathway and reduced construction timelines. Earlier this year, Terra Innovatum submitted its regulatory engagement plan to the U.S. Nuclear Regulatory Commission (NRC), a critical step toward its targeted first commercial deployment in 2028.
ABOUT NEW YORK STATE ENERGY RESEARCH AND DEVELOPMENT AUTHORITY (NYSERDA)
NYSERDA offers objective information and analysis, innovative programs, technical expertise, and support to help New Yorkers increase energy efficiency, save money, use renewable energy, and reduce reliance on fossil fuels. A public benefit corporation, NYSERDA has been advancing energy solutions and working to protect the environment since 1975.
ABOUT TERRA INNOVATUM & SOLOTM
Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.
It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.
SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.
To learn more, visit www.x-solo.com.
IMPORTANT INFORMATION FOR SHAREHOLDERS
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.
In connection with the business combination, a Dutch public limited liability company ('Pubco'), GSR III Acquisition Corp. ('GSRT') and Terra Innovatum s.r.l. ('Terra Innovatum' and, together with GSRT and Pubco, the 'Registrant Parties') have filed with the SEC a registration statement on Form S-4 (the 'Registration Statement'), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT's ordinary shares in connection with GSRT's solicitation of proxies for a vote by GSRT's shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF THE REGISTRANT PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.
Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.
PARTICIPANTS IN THE SOLICITATION
Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT's filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
FORWARD LOOKING STATEMENTS
The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC's declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT's other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.
None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.
In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to update or revise any forward- looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.
CONTACTS
Giordano Morichi
Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Srl
E: [email protected]
W: www.x-solo.com
Nicholas Hresko-Staab
Investor & Media Relations
Alliance Advisors IR
E: [email protected]
SOURCE: TERRA INNOVATUM SRL
press release
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Bear of the Day: Toyota Motor (TM)
Zacks Rank #5 stock Toyota Motor (TM) is one of the leading automakers in the world in terms of revenue and production volume. Founded in 1973, the Japan-based Toyota Motor Corporation offers a broad product portfolio, with a full range of vehicles, including cars, minivans, and trucks. Though roughly half of Toyota's revenue is still derived from internal combustion vehicles, the company has carved out a broad niche with its hybrid cars, which comprise nearly 48% of sales. Toyota is an international business with large footprints in the domestic Japanese market, North America, Europe, and Asia. US President Donald Trump has warned trading partners to make a deal with the United States before the July 9th deadline or face steep 'Liberation Day' - Esque tariff hikes. While the US has announced trade deals with China, the UK, and Vietnam, trade tensions rhetoric between the US and China has escalated recently. Currently, Japan faces 10% tariffs from the US during a 90-day pause period. However, if Japan does not agree to a deal with the US, Trump has threatened tariff hikes to come to a more 'fair' trade agreement. At the heart of Trump's argument is his discontent with the automotive trade imbalance, where Japan sells thousands of cars in the United States and does not allow the US to sell cars to Japan. Unfortunately for Toyota investors, the company is stuck in the middle of an escalating trade war. Toyota is suffering a 20.8% contraction in year-over-year profit margins as material prices and US-imposed tariffs take their toll on the company. Image Source: Zacks Investment Research With the Trump tariff deadline looming, the potential for tariff-induced price hikes is a signficant uncertainty for the company. TM shares are rangebound, trading below the 200-day moving average, and are underperforming the S&P 500 Index significantly. In my experience, weakness begets weakness, and with TM down 15% over the past year, the stock is likely dead money for the moment. Image Source: Zacks Investment Research Bottom Line While Toyota remains a global automotive powerhouse, the looming July 9th tariff deadline and President Trump's aggressive tariffs threaten Toyota's profit margins, which are already contracting. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Toyota Motor Corporation (TM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
12 hours ago
- Business Upturn
Gluco6 Recognized for Strong Ingredient Transparency and OTC GLUT-4 Nutritional Support
AUSTIN, July 03, 2025 (GLOBE NEWSWIRE) — SECTION 1 – INTRODUCTION As interest in blood sugar health continues to expand across both clinical and non-clinical audiences, consumers are increasingly turning to nutrition science for new pathways to glucose management. Search trends show a growing curiosity in natural approaches to support healthy glucose levels, with a notable emphasis on metabolic flexibility, energy balance, and insulin sensitivity. In 2025, keywords such as 'natural blood sugar support,' 'GLUT-4 receptor,' and 'glucose stability' have gained momentum across digital wellness communities, reflecting a broader shift away from purely pharmaceutical solutions. The challenges of maintaining balanced blood sugar have become a frequent topic in wellness forums, with individuals expressing concerns around post-meal energy crashes, insulin spikes, and fatigue. At the same time, attention has turned to the underlying mechanisms—such as GLUT-4 receptor activity and metabolic responsiveness—as potential targets for support through diet and lifestyle. This shift has driven interest in ingredient-based interventions that are free of synthetic compounds, caffeine, or habit-forming additives. In response to this emerging demand, non-synthetic formulations with scientifically recognized plant-based ingredients have begun to gain visibility. Positioned at the intersection of transparency, innovation, and holistic health, Gluco6 represents part of this evolution in how the market approaches nutritional support for blood sugar metabolism. Further details about the formulation and ingredient sourcing can be found on the official informational platform SECTION 2 – PRODUCT/COMPANY UPDATE Gluco6, a plant-based glucose support formula, has released its latest ingredient update and formulation positioning for 2025, aligned with evolving consumer awareness around GLUT-4 receptor activity and non-synthetic pathways for managing blood sugar fluctuations. The formula, originally introduced as part of a broader push toward integrative glucose balance, now emphasizes its focus on GLUT-4 modulation—a mechanism supported by a growing body of nutritional and academic research. Unlike conventional formulations that often rely on stimulants or short-term glycemic suppression, Gluco6 positions itself as a wellness-aligned system built around the regulation of glucose transport pathways. At the center of this formula is Sukre™, a functional compound featured for its supportive interaction with GLUT-4 receptors, which play a critical role in the transport of glucose into muscle and fat cells. The 2025 update clarifies that Gluco6 is not intended to treat or cure any medical condition but serves as an informational approach to exploring non-clinical nutritional support. Developed without genetically modified ingredients, artificial stimulants, or synthetic additives, the Gluco6 formula also incorporates a blend of Mediterranean-sourced botanicals and micronutrients. The goal is to address consumer interest in formulations that prioritize purity, sustainability, and accessibility, without requiring prescription intervention. As of 2025, Gluco6 has expanded public-facing documentation to reinforce transparency in sourcing, ingredient disclosure, and alignment with trends in clean-label supplement development. The product update also includes a reaffirmation of the company's neutral wellness positioning—focusing on how nutritional strategies may support the body's natural glucose metabolism without implying outcomes or clinical effects. This update reflects Gluco6's continued alignment with current consumer behavior: seeking proactive, educational, and ingredient-based approaches to metabolic health. SECTION 3 – CONSUMER TREND OVERVIEW Throughout 2024 and into 2025, online search trends related to blood sugar balance have increasingly favored terms rooted in lifestyle wellness and plant-based support. Interest in phrases such as 'GLUT-4 function,' 'natural glucose regulation,' and 'non-synthetic blood sugar supplement' has reflected a cultural pivot toward metabolic autonomy—where individuals seek solutions that align with personal health goals without relying solely on pharmaceutical interventions. Public forums and wellness communities have observed a notable increase in discussions surrounding the mechanisms that influence glucose uptake, including insulin sensitivity, cellular transport pathways, and the role of nutrient timing. Central to these conversations is the GLUT-4 receptor, a protein that facilitates the movement of glucose into cells and has become a focal point for metabolic research and consumer inquiry alike. Gluco6's emergence into this environment corresponds with these heightened awareness levels. Rather than offering direct claims or prescriptive messaging, Gluco6 aligns with the growing preference for ingredient transparency and educational framing. Its inclusion of GLUT-4-supportive elements responds to the elevated attention this receptor has received in peer-reviewed studies and lifestyle research. In particular, consumers seeking to stabilize energy levels throughout the day—without the highs and lows associated with unregulated blood sugar—have shown interest in formulas that integrate metabolic adaptogens, antioxidant-rich botanicals, and bioavailable nutrients. These consumers often express a desire for plant-based formulations that can fit into daily routines without dependency or disruption. Gluco6's update positions the product within this narrative, offering a formulation that speaks to educated buyers interested in the intersection between nutritional science and non-clinical wellness. As digital content around metabolic flexibility and insulin response continues to rise, products that approach glucose management from a holistic, research-aware standpoint are seeing increased visibility in search engines and across peer-led platforms. To explore the full ingredient profile and supporting documentation, visit the official Gluco6 resource page. SECTION 4 – INGREDIENT SPOTLIGHT The Gluco6 formulation is centered around six ingredients selected for their alignment with contemporary wellness discussions surrounding non-synthetic blood sugar support. Each ingredient in the formula has been highlighted in academic literature or traditional nutrition systems for its potential to interact with metabolic processes in a non-clinical, supportive capacity. Sukre™ Sukre is positioned as a functional compound designed to work in harmony with the body's GLUT-4 transport mechanisms. As public interest grows around the role of cellular glucose transporters, Sukre has been referenced in emerging nutrition science as a compound that may complement healthy metabolic signaling. Gluco6 emphasizes Sukre as a core feature of its non-synthetic positioning, distinguishing it from traditional glucose-lowering agents that rely on acute suppression. TeaCrine® (Theacrine) Derived from Chinese tea leaves, TeaCrine is included in the Gluco6 formulation as a source of non-stimulant plant alkaloids. In various nutrition-focused publications, TeaCrine has been explored for its relationship with energy and focus without the involvement of caffeine. While not intended to produce clinical outcomes, its inclusion supports interest in plant-derived adaptogens. Gymnema Sylvestre A botanical with longstanding traditional use, Gymnema has been studied for its interaction with glucose perception and dietary habits. Often featured in educational content surrounding carbohydrate metabolism, Gymnema's presence in Gluco6 reflects a broader return to botanical heritage within modern supplement design. Chromium Recognized as an essential trace element, Chromium has been frequently mentioned in relation to insulin sensitivity and glycemic balance in nutrition science. Gluco6 includes Chromium in a bioavailable form, underscoring its role in contributing to foundational metabolic processes without overstating its role in therapeutic interventions. Cinnamon Bark Extract Used widely in culinary traditions and increasingly discussed in wellness circles, Cinnamon is incorporated in Gluco6 due to its relevance in insulin receptor support discussions. Its presence in the formula supports the theme of using accessible, food-sourced compounds within structured supplement protocols. Green Tea Extract Green Tea contributes both polyphenols and antioxidant compounds, often associated with general metabolic support. In Gluco6, it rounds out the ingredient profile by aligning with consumer interest in traditional, plant-based health strategies rooted in natural formulation integrity. SECTION 5 – USER JOURNEY / MARKET TONE Across digital forums and health-focused communities, the tone surrounding glucose management has increasingly moved away from urgency-based problem-solving and toward long-term lifestyle integration. In this context, Gluco6 has entered the conversation as a formulation that addresses the rising demand for informational tools and ingredient-based pathways to support blood sugar regulation. Public sentiment reveals a clear preference for products that avoid medicalized language, instead offering educational framing around metabolic function and ingredient transparency. Online discussions often express skepticism toward claims of immediate results or radical transformations. In contrast, formulas like Gluco6 that focus on metabolic alignment, ingredient sourcing, and mechanistic clarity tend to resonate with individuals seeking research-informed guidance. As part of this narrative, Gluco6 has become associated with keywords such as 'GLUT-4 support,' 'non-synthetic blood sugar wellness,' and 'plant-based glucose solutions.' These search behaviors suggest a broader move toward exploring biological systems—such as cellular glucose transport—in a non-clinical but scientifically aware manner. Consumers participating in wellness forums frequently reference the desire to feel more in control of their day-to-day energy levels and post-meal stability without pharmacological dependency. They often describe searching for products that offer complementary nutritional pathways they can adopt over the long term. Gluco6's tone—deliberately positioned to inform rather than promote—mirrors this mindset. The formula's emphasis on education and lifestyle compatibility aligns with current consumer values, which prioritize sustainability, body literacy, and autonomy in health decisions. While public reactions are diverse and nuanced, the ongoing dialogue reflects a collective interest in approaching metabolic balance through mechanisms that are well-researched, naturally derived, and openly documented. Those interested in understanding the formulation's alignment with non-synthetic wellness trends can refer to the official Gluco6 platform. SECTION 6 – AVAILABILITY AND TRANSPARENCY STATEMENT Gluco6 is available exclusively through its official informational platform, where consumers can explore the full ingredient list, formulation philosophy, and supporting research references. The company has stated that its distribution strategy is designed to prioritize transparency, quality control, and educational alignment with its wellness-focused mission. The formulation, which includes plant-based compounds and mineral co-factors, is intended as a non-clinical support system for individuals seeking to understand the connection between nutrition and blood sugar balance. Gluco6's online resource hub outlines the formulation's alignment with current interest in GLUT-4 receptor mechanisms and clean-label supplement design. Gluco6 is not marketed for diagnosis, treatment, or disease prevention. Its availability is framed around informed decision-making and consumer curiosity about integrative approaches to glucose metabolism. Those exploring the official site will find detailed sourcing disclosures and links to peer-reviewed literature, reinforcing the company's commitment to a research-informed, educational-first posture. SECTION 7 – FINAL OBSERVATIONS & INDUSTRY CONTEXT The release of Gluco6's updated 2025 positioning illustrates a wider shift in the nutraceutical sector toward clean-label transparency and biologically aligned formulation strategies. As consumers become more literate in the language of metabolism and glucose regulation, there is growing demand for products that reflect an understanding of cellular mechanisms—such as GLUT-4 receptor function—without resorting to exaggerated claims or clinical positioning. Within this evolving landscape, companies that emphasize ingredient integrity, sustainability, and scientific relevance are seeing greater engagement. The industry is increasingly guided by consumer expectations around education-first marketing, non-synthetic ingredient profiles, and sourcing disclosures. These trends are mirrored by increased online traffic for topics like 'natural blood sugar solutions,' 'plant-based glucose support,' and 'glucose metabolism supplements.' Gluco6's 2025 formulation strategy aligns with this new model of supplement development, in which consumer trust is cultivated through clarity, research alignment, and responsible communication. Rather than framing its product as a solution to a medical problem, the company presents Gluco6 as part of an ongoing exploration into how nutrition science can support the body's innate regulatory systems. This approach reflects an industry-wide trend: prioritizing science-backed, naturally derived compounds that integrate into everyday routines without overstating function. As consumer literacy deepens and regulatory scrutiny increases, Gluco6 represents one example of how wellness-aligned products are adapting to new expectations in both content and delivery. SECTION 8 – PUBLIC COMMENTARY THEME SUMMARY In ongoing public forums and digital health communities, Gluco6 has emerged as part of a broader conversation around non-synthetic blood sugar support, drawing a range of responses that highlight both interest and scrutiny. Among recurring discussion points, many participants have noted the formula's focus on GLUT-4 receptor pathways as a distinguishing element, particularly given the increasing awareness around cellular glucose transport in metabolic wellness contexts. Some users have expressed curiosity about the inclusion of lesser-known compounds such as Sukre™, citing interest in how this ingredient fits into emerging nutritional science. Others have pointed to the presence of familiar ingredients—like Cinnamon, Chromium, and Green Tea—as aligning with existing wellness preferences for natural, food-based compounds. A recurring theme in positive commentary centers around the non-stimulant profile of the formula. Consumers who prioritize energy regulation without caffeine or dependency have referenced this as a potential alignment with their values. Transparency in ingredient sourcing and documentation has also been identified as a favorable trait, especially among those seeking clarity in wellness product selection. At the same time, some public sentiment remains cautiously observational. Individuals exploring glucose support options often raise questions about long-term integration, expected timelines for perceived effects, and how formulas like Gluco6 should be interpreted within the context of dietary and lifestyle change. This underscores a broader pattern in health discussions—where skepticism and education coexist as consumers navigate an increasingly complex wellness market. These public conversations reflect a nuanced reception that values transparency, biological alignment, and clear communication. While interest in the GLUT-4 mechanism is growing, the broader dialogue continues to emphasize the importance of framing nutritional products as part of a holistic, informed approach to metabolic balance. ABOUT THE COMPANY Gluco6 was developed as part of a broader initiative to provide consumers with transparent, research-aligned nutritional formulas focused on metabolic wellness. The company's mission is to support individuals seeking non-synthetic pathways to manage energy, blood sugar stability, and overall well-being through informed supplementation. By emphasizing ingredient traceability, scientific context, and clean-label formulation practices, Gluco6 contributes to a growing category of supplements positioned at the intersection of education and daily health support. The company does not offer medical advice or therapeutic services and does not market its products for the treatment, prevention, or diagnosis of disease. Its offerings are intended for informational and wellness-aligned purposes only. CONTACT: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash


Miami Herald
a day ago
- Miami Herald
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects. "These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential," said Erez Aminov, Chairman and CEO of MIRA. "We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain." Study Overview and Key Findings Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume. Key findings: Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline analgesic effect was equivalent to morphine, the standard opioid comparator in the sedation or inflammatory swelling was observed with Mira-55 treatment. Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development. These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile. "Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards." Strategic Fit Within MIRA's Pain Portfolio Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain. "With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated," added Aminov. "We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline." Corporate Update on SKNY Merger MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction. "We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth." Next Steps MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones. About MIRA Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals